How big is the Glucagon-like Peptide-1 Agonists Market?

The Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 11.99 billion in 2024 and grow at a CAGR of 1.12% to reach USD 12.63 billion by 2029. Read More

What is the current Glucagon-like Peptide-1 Agonists Market size?

In 2024, the Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 11.99 billion. Read More

Who are the key players in Glucagon-like Peptide-1 Agonists Market?

AstraZeneca, Eli Lilly and Company, Sanofi, Novo Nordisk A/S and Pfizer Inc. are the major companies operating in the Glucagon-like Peptide-1 Agonists Market. Read More

Which is the fastest growing region in Glucagon-like Peptide-1 Agonists Market?

Middle East and Africa is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Glucagon-like Peptide-1 Agonists Market?

In 2024, the North America accounts for the largest market share in Glucagon-like Peptide-1 Agonists Market. Read More

What years does this Glucagon-like Peptide-1 Agonists Market cover, and what was the market size in 2023?

In 2023, the Glucagon-like Peptide-1 Agonists Market size was estimated at USD 11.86 billion. The report covers the Glucagon-like Peptide-1 Agonists Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Glucagon-like Peptide-1 Agonists Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

What are the key factors driving the growth of the GLP-1 Agonist Market?

The key factors driving the growth of the GLP-1 Agonist Market are a) Rising diabetes prevalence b) Growing obesity concerns c) Expanding treatment options Read More

Glucagon-like Peptide-1 (GLP-1) AgonistsCompanies

This report lists the top Glucagon-like Peptide-1 (GLP-1) Agonists companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Glucagon-like Peptide-1 (GLP-1) Agonists industry.